Weekly Pharma Notes: Bristol-Myers Squibb, Johnson & Johnson, Merck And Roche

hile Merck launched its new anti-PD 1 therapy, Roche got European Union approval for expanded use of its rheumatoid Arthritis drug. Merck?s shares inched higher on the news and Bristol-Myers Squibb saw something similar. The reason could be that the latter is itself contemplating filing for approval for a similar drug this quarter.